•HRES 1140 IH 
Whereas the United States public health system has the ex-
pertise to eliminate TB, but many State TB programs 
have been left seriously under-resourced due to budget 
cuts at a time when TB cases are growing more complex 
to diagnose and treat; 
Whereas, although drugs, diagnostics and vaccines for TB 
exist, these technologies are antiquated and are increas-
ingly inadequate for controlling the global epidemic; 
Whereas the most commonly used TB diagnostic in the 
world, sputum microscopy, is more than 100 years old 
and lacks sensitivity to detect TB in most HIV/AIDS pa-
tients and in children; 
Whereas current tests to detect drug resistance take at least 
1 month to complete and faster drug susceptibility tests 
must be developed to stop the spread of drug resistant 
TB; 
Whereas the TB vaccine, BCG, provides some protection to 
children, but has little or no efficacy in preventing pul-
monary TB in adults; 
Whereas there is also a critical need for new TB drugs that 
can safely be taken concurrently with antiretroviral ther-
apy for HIV; 
Whereas the Global Health Initiative commits to reducing TB 
prevalence by 50 percent through 2015; 
Whereas enactment of the Lantos-Hyde Global Leadership 
Against HIV/AIDS, TB and Malaria Act and the Com-
prehensive TB Elimination Act provide an historic 
United States commitment to the global eradication of 
TB, including to the successful treatment of 4,500,000 
new TB patients and 90,000 new multi-drug resistant 
VerDate Nov 24 2008 
23:50 Mar 04, 2010
Jkt 089200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6300
E:\BILLS\HR1140.IH
HR1140
jbell on DSKDVH8Z91PROD with BILLS
•HRES 1140 IH 
(MDR) TB cases by 2013, while providing additional 
treatment through coordinated multilateral efforts; 
Whereas the United States Agency for International Develop-
ment provides financial and technical assistance to nearly 
40 highly burdened TB countries and supports the devel-
opment of new diagnostic and treatment tools, and is au-
thorized to support research to develop new vaccines to 
combat TB; 
Whereas the Centers for Disease Control and Prevention, 
working in partnership with States and territories of the 
United States, directs the national TB elimination pro-
gram and essential national TB surveillance, technical as-
sistance, prevention activities and supports the develop-
ment of new diagnostic, treatment and prevention tools 
to combat TB; 
Whereas the National Institutes of Health, through its many 
institutes and centers, plays the leading role in basic and 
clinical research into the identification, treatment and 
prevention of TB; and 
Whereas the Global Fund to Fight AIDS, Tuberculosis and 
Malaria provides 63 percent of all international financing 
for TB programs worldwide and finances proposals worth 
$3,200,000,000 in 112 countries, and TB treatment for 
6,000,000 and HIV/TB services for 1,800,000, and in 
many countries in which the Global Fund supports pro-
grams, TB prevalence is declining, as are TB mortality 
rates: Now, therefore, be it 
Resolved, That the House of Representatives— 
(1) commends the progress made by anti-tuber-
culosis programs, including the U.S. Agency for 
International Development, the Centers for Disease 
VerDate Nov 24 2008 
23:50 Mar 04, 2010
Jkt 089200
PO 00000
Frm 00004
Fmt 6652
Sfmt 6201
E:\BILLS\HR1140.IH
HR1140
jbell on DSKDVH8Z91PROD with BILLS
•HRES 1140 IH 
Control and Prevention and the Global Fund to 
Fight AIDS, Tuberculosis and Malaria; and 
(2) reaffirms its commitment to global tuber-
culosis control made through the Lantos-Hyde U.S. 
Leadership Against HIV/AIDS, Tuberculosis and 
Malaria Act of 2008. 
Æ 
VerDate Nov 24 2008 
23:50 Mar 04, 2010
Jkt 089200
PO 00000
Frm 00005
Fmt 6652
Sfmt 6301
E:\BILLS\HR1140.IH
HR1140
jbell on DSKDVH8Z91PROD with BILLS